CD13 Antigens (Alanine Aminopeptidase)

Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.

Also Known As:

Networked: 588 relevant articles (12 outcomes, 56 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Xu, Wenfang: 27 articles (01/2019 - 01/2005)
2.	Fang, Hao: 13 articles (06/2013 - 05/2007)
3.	Reinhold, Dirk: 11 articles (02/2012 - 01/2006)
4.	Berdel, Wolfgang E: 10 articles (06/2021 - 05/2009)
5.	Schwöppe, Christian: 10 articles (06/2021 - 05/2009)
6.	Zhang, Jian: 10 articles (10/2019 - 01/2010)
7.	Ansorge, Siegfried: 10 articles (02/2012 - 01/2006)
8.	Bank, Ute: 10 articles (02/2012 - 01/2006)
9.	Lendeckel, Uwe: 10 articles (01/2010 - 12/2003)
10.	Kessler, Torsten: 9 articles (06/2021 - 05/2009)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2013 - "Aminopeptidase N (APN) inhibitors have been reported to be effective in treating of life threatening diseases including cancer. " 06/07/2021 - "tTF-NGR, targeting tTF primarily at aminopeptidase N on angiogenic endothelial cells, was the first drug candidate from this emerging class of coaguligands translated to clinical studies in cancer patients. " 01/20/2004 - "In present study, PsA was found to inhibit mammalian aminopeptidase N (APN) that plays a key role in tumor cell invasion and angiogenesis. " 11/15/2023 - "Aminopeptidase N (APN/CD13) plays a role in tumors progression, but its inhibitor lacks cytotoxicity and is used as an adjuvant drug in cancer treatment. " 04/11/2023 - "An aminopeptidase N-based color-convertible fluorescent nano-probe for cancer diagnosis."
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2015 - "Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer." 11/01/2009 - "Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer." 07/01/2006 - "Clinical significance of aminopeptidase N in non-small cell lung cancer." 12/15/2005 - "Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer." 01/01/2015 - "The objective of this study was to analyze the expression of aminopeptidase N/CD13 (APN/CD13) in non-small cell lung cancer (NSCLC) and investigate its correlation with various clinical factors, including prognosis and efficacy of adjuvant chemotherapy. "
3.	Leukemia 01/01/2010 - "Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells." 04/28/2006 - "A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum." 09/01/1995 - "We have investigated the compartmentalization of aminopeptidase-N-like activity in various blood fractions obtained from patients with acute lymphoid (ALL) or myeloid (AML) leukemia. " 08/01/1990 - "Patients with CD34+ leukemia were more likely to have blasts expressing CD22, CD9, and CD13 antigens but were less likely to coexpress CD20. " 07/01/1993 - "A newly established human leukemia cell line, OM9;22, is reported, with B-precursor immunophenotype (CD10+ CD19+ CD22+ HLA- DR+ C mu-) and CD13 antigen, originated from a 19-year-old female patient with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL). "
4.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/01/1995 - "Because acute experimental autoimmune encephalomyelitis (EAE) is characterized by a transient and focal perturbation of the BBB, we have utilized the model of adoptive transfer EAE to correlate the expression of the pericytic aminopeptidase N (pAP N) with the acute functional state of the BBB. " 06/01/1995 - "Changes in the expression pattern of blood-brain barrier-associated pericytic aminopeptidase N (pAP N) in the course of acute experimental autoimmune encephalomyelitis." 03/01/2011 - "PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice." 01/01/2009 - "Moreover, these inhibitors are capable of attenuating the severity of autoimmune diseases, such as experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis, and experimental arthritis, a model of human rheumatoid arthritis, in vivo, particularly in combination with inhibitors of aminopeptidase N (APN, CD13) enzymatic activity. "
5.	Nephrotic Syndrome (Syndrome, Nephrotic) 10/07/1991 - "[Activity of alanine aminopeptidase, beta-glucuronidase and N-acetyl-beta-d-glucosaminidase in urine of children with nephrotic syndrome]." 10/07/1991 - "Activity of alanine aminopeptidase (AAP), beta-glucuronidase, and N-acetyl-beta-D-glucosaminidase (NAG) in daily urine has been determined in 27 children with nephrotic syndrome, 14 children in remission, and 11 healthy children. " 01/01/1993 - "To determine the diagnostic role of urinary trehalase in chronic glomerular disease, urinary trehalase activity and other urinary markers such as N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (gamma-GTP), lactate dehydrogenase (LDH), lysozyme and beta 2-microglobulin (BMG) were measured in patients with chronic glomerulonephritis, nephrotic syndrome and chronic renal failure. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
3.	antiarrhythmic peptide (AAP)
4.	ubenimex
5.	Acetylglucosaminidase (NAGase)
6.	Peptide Hydrolases (Proteases)
7.	aminopeptidase B
8.	Cytokines
9.	Transferases
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Therapeutics
2.	Adjuvant Chemotherapy
3.	Metronomic Administration
4.	Neoadjuvant Therapy
5.	Immunotherapy